Deals Shaping The Medical Industry, March 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2015.
You may also be interested in...
Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.
The TGA has taken a series of actions to address supply chain issues, including on the regulatory front, but it says more remains to be done and is asking stakeholders for suggestions in a new online survey.
Recent executive moves in the industry include new CEOs at Latigo Biotherapeutics and YS Biopharma Co, plus new directors at Cingulate.